Randomized Comparison of Clopidogrel Versus Ticagrelor or Prasugrel in Patients of 70 years or Older With Non-ST-Elevation Acute Coronary Syndrome - POPular AGE
Contribution To Literature:
The POPular AGE trial showed that clopidogrel was associated with less bleeding and similar ischemic events vs. a more potent P2Y12 inhibitor among the elderly.
The goal of the trial was to evaluate clopidogrel compared with ticagrelor or prasugrel among patients ≥70 years of age being treated for a non-ST-segment elevation acute coronary syndrome (NSTE-ACS).
Patients ≥70 years of age with an NSTE-ACS were randomized to clopidogrel (n = 500) versus ticagrelor or prasugrel (n = 502) for 12 months.
- Total number of enrollees: 1,002
- Duration of follow-up: 12 months
- Mean patient age: 77 years
- Percentage female: 37%
- Percentage with diabetes: 29%
- Patients ≥70 years of age with an NSTE-ACS
- Contraindication to a P2Y12 inhibitor
- Dual antiplatelet therapy use prior to presentation
- Indication for major surgery
- Limited life expectancy (<1 year)
The co-primary safety outcome of PLATO major and minor bleeding occurred in 18% of the clopidogrel group compared with 24% of the ticagrelor/prasugrel group (p = 0.018).
The co-primary net clinical benefit outcome of death, myocardial infarction, stroke, or PLATO major and minor bleeding occurred in 27% of the clopidogrel group compared with 32% of the ticagrelor/prasugrel group (p for noninferiority = 0.025).
- PLATO major bleeding: 8% of the clopidogrel group compared with 12% of the ticagrelor/prasugrel group (p = 0.11)
- Fatal bleeding: 0% of the clopidogrel group compared with 1.0% of the ticagrelor/prasugrel group (p = 0.03)
- Death, myocardial infarction, or stroke: 11% of the clopidogrel group compared with 12% of the ticagrelor/prasugrel group (p = 0.71)
- Adherence: 78% in the clopidogrel group vs. 53% in the ticagrelor/prasugrel group
Among elderly patients (≥70 years of age) being treated for an NSTE-ACS, long-term treatment with clopidogrel was associated with less PLATO major/minor bleeding and less fatal bleeding vs. a more potent P2Y12 inhibitor (i.e., ticagrelor or prasugrel). With regard to net clinical benefit, clopidogrel was noninferior compared with a more potent P2Y12 inhibitor. More patients in the potent P2Y12 inhibitor group switched to another agent due to bleeding, need for a novel oral anticoagulant, or dyspnea.
In summary, for elderly patients who require treatment with a P2Y12 inhibitor, long-term use of clopidogrel appears to be reasonable.
Gimbel M, Qaderdan K, Willemsen L, et al. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. Lancet 2020;395:1374-81.
Presented by Dr. Marieke E. Gimbel at the European Society of Cardiology Congress, Paris, France, August 31, 2019.
Keywords: ESC Congress, ESC 19, Acute Coronary Syndrome, Adenosine, Anticoagulants, Dyspnea, Geriatrics, Hemorrhage, Myocardial Infarction, Myocardial Ischemia, Stroke, Vascular Diseases
< Back to Listings